Magnitude of risks and benefits of the addition of bevacizumab (BEVA) to chemotherapy (CT) for patients (pts) with advanced breast cancer (ABC): Metaregression analysis of randomized trials (RCT).

Published 2017 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Magnitude of risks and benefits of the addition of bevacizumab (BEVA) to chemotherapy (CT) for patients (pts) with advanced breast cancer (ABC): Metaregression analysis of randomized trials (RCT).
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 28, Issue 15_suppl, Pages 1045-1045
Publisher
American Society of Clinical Oncology (ASCO)
Online
2017-02-24
DOI
10.1200/jco.2010.28.15_suppl.1045

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.